GlassScriptPhysician profile
Michael A Sumsion
NPI 1699725507
$4,105.83
in general payments reported to CMS, 2019-2025
23 companies · $1,594 in 2025
The $1,594 reported for 2025 was more than what 86% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69.78 · 2020: $96.77 · 2021: $178 · 2022: $668 · 2023: $708 · 2024: $790 · 2025: $1,594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,075 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,074.50 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $577.99 | 2022-2025 | Ozurdex |
| Bausch & Lomb Americas INC. | $532.66 | 2022-2025 | Vyzulta, Miebo, Lotemax Sm |
| Biotissue Holdings INC. | $398.90 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $365.40 | 2022-2025 | Eylea Hd, Eylea |
| Mallinckrodt Hospital Products INC. | $295.92 | 2023-2025 | Acthar |
| Apellis Pharmaceuticals, INC. | $265.15 | 2022-2025 | Syfovre |
| Alcon Vision LLC | $205.85 | 2025 | Rocklatan, Rhopressa, Tryptyr |
| Astellas Pharma US INC | $199.99 | 2023-2025 | Izervay |
| Eyepoint US, INC. | $163.06 | 2022-2023 | |
| New World Medical,INC. | $160.85 | 2025 | Ahmed Glaucoma Valve, Clearpath, Kahook Dual Blade |
| Sun Pharmaceutical Industries INC. | $133.07 | 2020-2024 | |
| Carl Zeiss Meditec USA, INC. | $126.44 | 2025 | Veracity Surgical |
| Johnson & Johnson Surgical Vision, INC. | $107.44 | 2021-2024 | Veritas Vision System |
| Novartis Pharmaceuticals Corporation | $98.51 | 2022-2023 | |
| Allergan, INC. | $96.46 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $88.24 | 2022-2024 | Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3, Istent Infinite Trabecular Micro-Bypass System Model Is3, Istent Trabecular Micro-Bypass System Model Is3 |
| Genentech USA, INC. | $74.13 | 2019-2025 | Vabysmo |
| Carl Zeiss Meditec, INC. | $60.00 | 2022 | |
| Dompe US, INC. | $51.97 | 2022-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $39.02 | 2025 | Xdemvy |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Shire North American Group INC | $13.86 | 2019 | |
| Alimera Sciences, INC. | $12.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sumsion listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.